Novel Drug Delivery Systems(NDDS):

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

New Molecular Entity (NME) Platforms:

NCE platform: new chemical entity based on innovative targets，including novel small molecule compounds and biologics such as antibodies and nucleic acids; NTE platform: novel therapeutic entities with molecular modifications;PDC platform: peptide-conjugated drugs; Key capabilities set up for target discovery, drug design, screening and evaluation, contributing 10+ candidate drugs to the pipeline;

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

BA-huMab® platform: Induces a rapid immune response and produces high antibody titers after immunization; A large number of antibodies were validated on the project; Phage display technology platform: Use of novel vaccine and immunoadjuvant technologies; Mature phage library construction; High-throughput and diverse phage based panning strategies; A total of light chain double resistance development capabilities;

Bispecific T-cell Engager Technology Platform:

Demonstrate high avidity with tumor target antigen by bivalent binding to achieve better drug efficacy; Demonstrate low affinity with T cells by monovalent binding to lower toxicity; Reduce CD3 antibody binding affinity, to significantly reduce the risk of CRS; CD3 triple antibody targeting 2 tumor targets was developed to kill highly heterogeneous tumors more efficiently;

ADC Technology Platform:

A Top 1 inhibitor cytotoxic payload with excellent properties; Antibodies with high internalizing potential; A dual-antibody ADC with a common light chain was used to deal with highly heterogeneous tumors; Fixed point coupling technique; Process development and quality analysis for ADC products;

Nucleic Acid Therapy and Gene Therapy:

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Cellular Immunotherapies:

Developing next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;